Cargando…
Safety of COVID-19 Vaccination in Immune-Deficient Patients Receiving Supplemental Immunoglobulin Therapies
Autores principales: | Squire, Jacqueline D., Joshi, Avni Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294866/ https://www.ncbi.nlm.nih.gov/pubmed/34291391 http://dx.doi.org/10.1007/s10875-021-01101-8 |
Ejemplares similares
-
Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency
por: Squire, Jacqueline, et al.
Publicado: (2021) -
Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products
por: Manian, Deepti Vellaichamy, et al.
Publicado: (2021) -
COVID-19 in CVID: a Case Series of 17 Patients
por: Greenmyer, Jacob R., et al.
Publicado: (2021) -
Dog bite, immunoglobulin, and preexposure vaccination
por: Pokee, Nora, et al.
Publicado: (2015) -
Cerebral Venous Thrombosis after Intravenous Immunoglobulin Therapy in Immune Thrombocytopenic Purpura
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2018)